期刊文献+

中国上海地区乳腺癌的临床病理特征分析 被引量:1

Clinicopathological characteristics of breast cancer from Shanghai region of China:a retrospective analysis
下载PDF
导出
摘要 目的研究上海地区乳腺癌患者的临床病理特征。方法统计2008年至2010年上海地区1122例乳腺癌患者的相关临床病理特征,并分析它们之间的联系。结果男性乳腺癌比例为0.89%,低于其他地区。患者发病平均年龄为53岁(中位55岁),其中51~70岁人数最多,占43.85%。就诊时绝大多数为Ⅱ期,其中49.02%患者伴有淋巴结转移。病理分型中浸润性非特殊癌占94.47%,其中浸润性导管癌为90.91%,与国内其他地区相比,特殊类型癌比较少,占3.57%。中位肿瘤直径为3cm,巨大型肿瘤较少。三阴性乳腺癌占18.81%,ER、PR、HER-2的阳性表达率分别为48.6%、59.4%和23.5%。术后病理分期与ER表达呈负相关,与HER-2呈正相关,与PR、Ki-67、E-cadherin、p53、TOPO-Ⅱ、p27、CK5/6均无关。组织学分级可能与E-cadherin有关(P=0.051),与其他表达无关。淋巴结转移与HER-2表达呈正相关;肿瘤大小与ER表达呈负相关,与HER-2表达呈正相关。ER表达与PR呈正相关,与HER-2、Ki-67及p53呈负相关。HER-2与ER、PR、CK5/6表达呈负相关,与Ki-67、TOPO-Ⅱ呈正相关。Ki-67与TOPO-Ⅱ、HER-2表达呈正相关,与ER、p53、p27呈负相关。结论上海地区乳腺癌患者的临床病理特征具有地域性,联合检测ER、PR、HER-2、Ki-67和p53对其诊断并指导治疗具有一定的临床意义。 Objective To study clinicopathological characteristics of breast cancer in Shanghai region. Methods The clini copathological characteristic of 1122 cases of breast cancer patients which diagnosed from 2008 to 2010 in Shanghai region was ana lyzed. Results The onset in male was 0. 89%. The average age was 53 years old( median age 55 years old). The onset population of 5170 years was about 43.85%. Most of patients was in stage lI and half of them had lymph nodes metastasis. Non special type of in filtration caner was about 94.47% ,and 90. 91% of them were infiltration duct cancer. Special type of cancer was less than other region in China. The median diameter of tumor was 3era, huge mass were seldom found. Triple negative breast cancer was about 18.81%. The positive expression rate of ER, PR and HER2 was 48.6% ,59.4% and 23.5% , respectively. Pathological staging of triplenega tive breast cancer was correlated negatively with ER and positively with HER2 and was no significantly related to PR, Ki67, Ecadher in. HER2 expression was correlated positively with tumor size. Expression of ER was correlated positively with PR and negatively with HER2, Ki67 and p53. Expression of HER2 was negatively correlated with ER, PR and CK5/6 and positively with Ki67, TOPO H. Expression of Ki67 was correlated positively with TOPOII and HER2 and negatively with ER,p53 and p27. ER,PR,HER2 ,Ki67 and p53 had correlation with clinicopathologic index such as histopathologic type, tumor size and axillary lymphnode metastasis. Con elusion Ciinicopathological characteristics of breast cancer in Shanghai region have some special features, and joint detection of ER, PR, HER2,Ki67 and p53 is very important for diagnosis and treatment in breast cancer.
出处 《临床肿瘤学杂志》 CAS 2012年第5期437-441,共5页 Chinese Clinical Oncology
关键词 乳腺癌 临床病理特征 基因表达 免疫组织化学 Breast cancer Clinicopathology Gene expression Imunohistochemlstry
  • 相关文献

参考文献22

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin,2011,61(3) :69 -90.
  • 2Fan L, Zheng Y, Yu KD, et al. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China[ J]. Breast Cancer Res Treat, 2009, 117 (2) :409 - 416.
  • 3刘红,荀培,陈可欣,李海欣,郝希山.天津市近20年女性乳腺癌患者临床病理特点及预后变化趋势分析[J].中华医学杂志,2007,87(34):2405-2407. 被引量:13
  • 4Rakha EA, E1-Sayed ME, Green AR, et al. Biologic and clini- cal characteristics of breast cancer with single hormone receptor- positive phenotype [ J ]. J Clin Oncol, 2007,25 ( 30 ) : 4772 - 4778.
  • 5Dowsett M, Allred DC, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 ( HER-2 ) status with recurrence in the arimidex, tamoxifen, alone or in combination trial[J]. J Clin 0ncol,2008,26(7) :1059 -1065.
  • 6Stuart-Harris R, Palmqvist BS, Ross HA. The prognostic signifi- cance of single hormone receptor positive metastatic breast canc- er: An analysis of three randomised phase Ⅲ trials of aromatase inhibitors[ J]. The Breast,2009,18 (6) : 351 - 355.
  • 7Gennari A, Sormani M P, Pronzato P, et al. HER2 status and ef- ficacy of adjuvant anthraeyclines in early breast cancer: A pooled analysis of randomized trials [ J ]. J Natl Cancer Inst, 2008,100 (1) : 14 -20.
  • 8Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade [ J]. J Clin Oncol, 2007,25 (10) : 1239 -1246.
  • 9De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: Where are we? [J]. J Clin Oncol, 2010,28 ( 28 ) :4289 - 4292.
  • 10Millar E, Graham PH, O'Toole SA, et al. Prediction of local re- currence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomark-er panel[ J ]. J Clin 0ncol,2009,27 (28) :4701 - 4708.

二级参考文献12

  • 1张保宁.乳腺癌临床研究的回顾与展望[J].中华医学杂志,2005,85(1):7-8. 被引量:47
  • 2上海市肿瘤研究所流行病学研究室.2000年上海市恶性肿瘤发病率[J].肿瘤,2003,23:532-532.
  • 3Pakin DM, Pisani P, Ferlay J, et al . Estimates of the worldwide incidence of 25 major cancers in1990. Int J Cancer, 1999, 80:827- 841.
  • 4王庆生.乳腺癌流行病学//李树玲,主编.乳腺肿瘤学.北京:科学技术文献出版社,2000:352-375.
  • 5National Institute of Health Consensus Development Conference.J Natl Cancer Inst Monogr,2001,30 : 1-30.
  • 6Gabe R.Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Annals of Oncology, 2005, 16 (Suppl2) : 153-162.
  • 7Singletary ES, Connolly JL. Breast Cancer Staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin ,2006,56:37-47.
  • 8Bland KI, Menck HR, Scott-Conner CE, et al. The National cancer data base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer, 1998,83: 1262-1273.
  • 9Pakin DM, Pisani P, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin, 1999,49:33-64.
  • 10Fremgen AM, Bland KI McGitmis IS, et al. Clinical highlights from the National Cancer Data Base. CA Cancer J Cl, 1999,49: 145- 158.

共引文献12

同被引文献9

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部